Thursday, 18 Oct 2018

You are here

Registry Efficacy of Rituximab in Refractory SLE

Rituximab (RTX) treatment of lupus (SLE) patients remains a therapeutic option, especially in refractory SLE.  An observational UK cohort of 261 refractory SLE patients were followed in the BILAG-BR registry.

Patients starting biologic therapy between 2010 and 2015 were enrolled. Glucocorticoids were used in 93% of patients.

Response rates at 6 months were available for 68% of patients. After 6 mos. of RTX, median BILAG scores dropped from at baseline to 3 at 6 months (P < 0.0001).

During the same period the median SLEDAI-2K reduced from 8 to 4 (0-7) (P < 0.001).

Half (49%) of patients achieved a response along with a significant reduction of glucocorticoid dose to 7.5 mg at 6 months (P < 0.001).

Serious infections occurred in 10% patients.

Despite large randomized trials failing to show the efficacy of RTX in SLE (LUNAR https:/buff.ly/2BDE725 and EXPLORER https://buff.ly/2BCHy99), uncontrolled observational data suggests possible efficacy and safety of RTX in refractory SLE.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Teenage Obesity Increases Lupus Risk

Analysis of the Black Women's Health Study shows that obesity as a teenager may be associated with increased risk of systemic lupus erythematous (SLE) in adulthood.

The relationship between obesity and SLE risk is unclear. Past studies have predominantly assessed white women, while black women have higher prevalence of both obesity and SLE.

SLE-Scleroderma Overlap Outcomes

Overlap of autoimmune disorders represents a significant diagnostic and management challenge to the rheumatologist. A novel cohort analysis of overlap between systemic sclerosis (SSc) and systemic lupus erythematous (SLE) suggests such patients tend to be younger, more frequently have PAH, but less cutaneous manifestations of SSc.

Excess Mortality in CTD or Systemic Vasculitis Patients

The Norwegian connective tissue disease (CTD) and systemic vasculitis (PSV) registry (NOSVAR) studied patient outcomes over a 15 year period and found overall mortality to be higher in the CTD compared to the PSV group.

Mortality Improves in Lupus ESRD

The past two decades have seen a significant decline in mortality among patients with lupus nephritis, U.S. registry data indicated.

Ustekinumab May be Effective in Lupus

Ronald F van Vollenhoven and colleagues have reported in Lancet that ustekinumab (UST), an interleukin-12 and -23 inhibitor, when added to usual therapy in systemic lupus erythematosus (SLE) patients, was shown to be superior to placebo at improving clinical efficacy and laboratory parameters after 6 months of therapy.